250 related articles for article (PubMed ID: 38577664)
1. Unveiling the next generation of MRI contrast agents: current insights and perspectives on ferumoxytol-enhanced MRI.
Si G; Du Y; Tang P; Ma G; Jia Z; Zhou X; Mu D; Shen Y; Lu Y; Mao Y; Chen C; Li Y; Gu N
Natl Sci Rev; 2024 May; 11(5):nwae057. PubMed ID: 38577664
[TBL] [Abstract][Full Text] [Related]
2. Ferumoxytol-Enhanced MRI in Children and Young Adults: State of the Art.
Adams LC; Jayapal P; Ramasamy SK; Morakote W; Yeom K; Baratto L; Daldrup-Link HE
AJR Am J Roentgenol; 2023 Apr; 220(4):590-603. PubMed ID: 36197052
[TBL] [Abstract][Full Text] [Related]
3. How to stop using gadolinium chelates for magnetic resonance imaging: clinical-translational experiences with ferumoxytol.
Daldrup-Link HE; Theruvath AJ; Rashidi A; Iv M; Majzner RG; Spunt SL; Goodman S; Moseley M
Pediatr Radiol; 2022 Feb; 52(2):354-366. PubMed ID: 34046709
[TBL] [Abstract][Full Text] [Related]
4. Safety of Off-Label Use of Ferumoxtyol as a Contrast Agent for MRI: A Systematic Review and Meta-Analysis of Adverse Events.
Ahmad F; Treanor L; McGrath TA; Walker D; McInnes MDF; Schieda N
J Magn Reson Imaging; 2021 Mar; 53(3):840-858. PubMed ID: 33098154
[TBL] [Abstract][Full Text] [Related]
5. The use of ferumoxytol for high-resolution vascular imaging and troubleshooting for abdominal allografts.
Shah A; Neitzel E; Panda A; Fananapazir G
Abdom Radiol (NY); 2024 Apr; ():. PubMed ID: 38561553
[TBL] [Abstract][Full Text] [Related]
6. Vascular applications of ferumoxytol-enhanced magnetic resonance imaging of the abdomen and pelvis.
Bowman AW; Gooch CR; Alexander LF; Desai MA; Bolan CW
Abdom Radiol (NY); 2021 May; 46(5):2203-2218. PubMed ID: 33090256
[TBL] [Abstract][Full Text] [Related]
7. Ferumoxytol-Enhanced Magnetic Resonance Imaging in Late-Stage CKD.
Mukundan S; Steigner ML; Hsiao LL; Malek SK; Tullius SG; Chin MS; Siedlecki AM
Am J Kidney Dis; 2016 Jun; 67(6):984-8. PubMed ID: 26786296
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Three Ultrasmall, Superparamagnetic Iron Oxide Nanoparticles for MRI at 3.0 T.
Colbert CM; Ming Z; Pogosyan A; Finn JP; Nguyen KL
J Magn Reson Imaging; 2023 Jun; 57(6):1819-1829. PubMed ID: 36250695
[TBL] [Abstract][Full Text] [Related]
9. Potential for differentiation of pseudoprogression from true tumor progression with dynamic susceptibility-weighted contrast-enhanced magnetic resonance imaging using ferumoxytol vs. gadoteridol: a pilot study.
Gahramanov S; Raslan AM; Muldoon LL; Hamilton BE; Rooney WD; Varallyay CG; Njus JM; Haluska M; Neuwelt EA
Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):514-23. PubMed ID: 20395065
[TBL] [Abstract][Full Text] [Related]
10. A comparison of ferumoxytol with gadolinium as contrast agents for the diagnostic magnetic resonance imaging of osteomyelitis.
Langsjoen J; Neuwelt A; Eberhardt S; Mlady G; Shukla U; Murali S; Pizanis C; Sillerud LO
Magn Reson Imaging; 2020 Sep; 71():45-54. PubMed ID: 32439428
[TBL] [Abstract][Full Text] [Related]
11. Combined iron oxide nanoparticle ferumoxytol and gadolinium contrast enhanced MRI define glioblastoma pseudoprogression.
Barajas RF; Hamilton BE; Schwartz D; McConnell HL; Pettersson DR; Horvath A; Szidonya L; Varallyay CG; Firkins J; Jaboin JJ; Kubicky CD; Raslan AM; Dogan A; Cetas JS; Ciporen J; Han SJ; Ambady P; Muldoon LL; Woltjer R; Rooney WD; Neuwelt EA
Neuro Oncol; 2019 Mar; 21(4):517-526. PubMed ID: 30277536
[TBL] [Abstract][Full Text] [Related]
12. Ferumoxytol use as an intravenous contrast agent for magnetic resonance angiography.
Stabi KL; Bendz LM
Ann Pharmacother; 2011 Dec; 45(12):1571-5. PubMed ID: 22045905
[TBL] [Abstract][Full Text] [Related]
13. Comparative analysis of ferumoxytol and gadoteridol enhancement using T1- and T2-weighted MRI in neuroimaging.
Hamilton BE; Nesbit GM; Dosa E; Gahramanov S; Rooney B; Nesbit EG; Raines J; Neuwelt EA
AJR Am J Roentgenol; 2011 Oct; 197(4):981-8. PubMed ID: 21940589
[TBL] [Abstract][Full Text] [Related]
14. USPIOs as targeted contrast agents in cardiovascular magnetic resonance imaging.
Lu Y; Huang J; Neverova NV; Nguyen KL
Curr Cardiovasc Imaging Rep; 2021 Feb; 14(2):. PubMed ID: 33824694
[TBL] [Abstract][Full Text] [Related]
15. Emerging applications for ferumoxytol as a contrast agent in MRI.
Bashir MR; Bhatti L; Marin D; Nelson RC
J Magn Reson Imaging; 2015 Apr; 41(4):884-98. PubMed ID: 24974785
[TBL] [Abstract][Full Text] [Related]
16. Ferumoxytol-enhanced magnetic resonance angiography provides comparable vascular conspicuity to CT angiography in dogs with intrahepatic portosystemic shunts.
Wilson S; Culp WTN; Wisner ER; Cissell DD; Finn JP; Zwingenberger AL
Vet Radiol Ultrasound; 2021 Jul; 62(4):463-470. PubMed ID: 33634935
[TBL] [Abstract][Full Text] [Related]
17. Contrast-enhanced MR Angiography without Gadolinium-based Contrast Material: Clinical Applications Using Ferumoxytol.
Jalili MH; Yu T; Hassani C; Prosper AE; Finn JP; Bedayat A
Radiol Cardiothorac Imaging; 2022 Aug; 4(4):e210323. PubMed ID: 36059381
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular MRI with ferumoxytol.
Finn JP; Nguyen KL; Han F; Zhou Z; Salusky I; Ayad I; Hu P
Clin Radiol; 2016 Aug; 71(8):796-806. PubMed ID: 27221526
[TBL] [Abstract][Full Text] [Related]
19. High-resolution, whole-body vascular imaging with ferumoxytol as an alternative to gadolinium agents in a pediatric chronic kidney disease cohort.
Nayak AB; Luhar A; Hanudel M; Gales B; Hall TR; Finn JP; Salusky IB; Zaritsky J
Pediatr Nephrol; 2015 Mar; 30(3):515-21. PubMed ID: 25212105
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
